期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 13, 期 6, 页码 1042-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2013.09.006
关键词
Crohn's Disease; Therapy; Prevention and Control; Mucosal Healing; Treat to Target
资金
- Abbott Laboratories
- Ferring
- MSD Pharma
- Abbott (AbbVie)
- Actogenix
- Albireo Pharma
- Amgen
- Astra Zeneca
- Athersys
- Avaxia Biologics Inc
- Axcan
- Boehringer-Ingelheim France
- Bristol-Myers Squibb
- Celgene
- Centocor
- Elan/Biogen
- Ferring Pharma A/S
- Genentech
- GiCare Pharma
- Gilead
- Given Imaging Inc
- GSK
- Ironwood Pharma
- JnJ/Janssen
- Merck
- Millennium
- Nektar
- Novonordisk
- Prometheus Therapeutics and Diagnostics
- Pfizer
- Salix Pharma
- Serono
- Shire
- Sigmoid Pharma
- Synergy Pharma Inc
- Takeda
- Teva Pharma
- Tillotts
- UCB Pharma
- Unity Pharmaceuticals
- Warner-Chilcott
- Wyeth
- Zealand Pharm
- Zyngenia
- Abbott
- CombinatoRx
- Milllennium
- Novartis
- Protein Design Labs
- AbbVie
- Janssen
- BMS
- Roche
- Astellas
- UCB
- Mitsubishi
- Norgine
- Tillots
- Vifor
- Therakos
- Pharmacosmos
- Pilege
- UCB-Pharma
- Hospira
- Astellas Pharma
- Baxter
- Bristol-Meyers Squibb
- Coronado Biosciences
- Elan Pharmaceuticals
- Eli Lilly
- Ferring Pharmaceuticals
- Glaxo Smith Kline
- Ironwood Pharmaceuticals
- Meda Pharmaceuticals
- Millennium Pharmaceuticals
- Novo Nordisk A/S
- NPS Pharmaceuticals
- Prometheus Laboratories
- Receptos
- Sanofie
- Santarus
- Shire Pharmaceuticals
- S. L. A. Pharma (UK) Limited
- Vertex
- Warner Chilcott UK Limited
- Prometheus Labs
- ActoGeniX NV
- AGI Therapeutics, Inc
- Alba Therapeutics Corporation
- Albireo
- Alfa Wasserman
- AM-Pharma BV
- Anaphore
- Athersys, Inc
- Atlantic Healthcare Limited
- Aptalis
- BioBalance Corporation
- Boehringer-Ingelheim Inc
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- ChemoCentryx
- CoMentis
- Cosmo Technologies
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- Eisai Medical Research Inc
- EnGene, Inc
- Enteromedics
- Exagen Diagnostics, Inc
- Flexion Therapeutics, Inc
- Funxional Therapeutics Limited
- Genzyme Corporation
- Gilead Sciences
- Given Imaging
- Human Genome Sciences
- KaloBios Pharmaceuticals, Inc
- Lexicon Pharmaceuticals
- Lycera Corporation
- Merck Research Laboratories
- MerckSerono
- Nisshin Kyorin Pharmaceuticals Co, Ltd
- Optimer Pharmaceuticals
- Orexigen Therapeutics, Inc
- PDL Biopharma
- Procter
- Gamble
- ProtAb Limited
- Purgenesis Technologies, Inc
- Relypsa, Inc
- Salient Pharmaceuticals
- Salix Pharmaceuticals, Inc
- Schering Plough Corporation
- Sigmoid Pharma Limited
- Sirtris Pharmaceuticals, Inc (a GSK company)
- Targacept
- Teva Pharmaceuticals
- Tillotts Pharma AG
- TxCell SA
- Viamet Pharmaceuticals
- Vascular Biogenics Limited (VBL)
- Gamble Pharmaceuticals
- Zeria Pharmaceutical Co, Ltd
The traditional management of Crohn's disease, which is based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms, does not improve long-term outcomes of Crohn's disease and places patients at risk for bowel damage. The introduction of novel therapies and the development of new approaches to treatment in rheumatoid arthritis led to better outcomes for patients. Prominent among these is a treat to target strategy that is based on regular assessment of disease activity by using objective clinical and biological outcome measures and the subsequent adjustment of treatments. This approach is complementary to the concept of early intervention in high-risk patients. This review evaluates current literature on this topic and proposes a definition for the concept of treating to targets for Crohn's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据